Long-term outcome of renal cell carcinoma in patients with H
This retrospective study included 67 patients with RCC, both HIV positive or negative, who underwent surgical treatment. Of 261 consecutive patients, 18 patients who forwent treatment before surgery, 133 cases with incomplete data, 16 patients classified as clinical stage IV, 11 PLWH patients who did not receive antiretroviral therapy, and 16 patients with metastasis were excluded from the main analysis. Of the remaining 67 patients, 33 individuals had HIV and the other 34 did not. The median overall survival was 74.9 months (95% confidence interval [CI]=64.6 to 85.2) in PLWH and 96.4 months (95% CI=90.0 to 102.9) in the HIV-negative group. Progression-free survival was 66.4 months (95% CI=53.5 to 79.3) and 90.6 months (95% CI=81.1 to 100.1), respectively. RCC patients with HIV who underwent surgery had a shorter survival time (hazard ratio [HR]=2.8, 95% CI=1.1 to 7.0, p=0.016) and an increased incidence of tumor progression (HR=2.7, 95% CI=1.1 to 6.8, p=0.028). Univariate and multivariate Cox regression analyses showed that a lower ratio of CD4+ T cells to CD8+ T cells (adjusted odds ratio=0.092, 95% CI=0.01 to 0.70, p=0.022) was associated with worse survival among PLWH. In this retrospective analysis of RCC patients who underwent surgery, PLWH had worse overall survival and shorter progression-free survival compared to HIV-negative cases.

Source: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07592-z